Longeveron Inc. announces Chief Medical Officer departure
On October 7, 2026, Dr. Nataliya Agafonova informed management of her decision to step down as Chief Medical Officer of Longeveron Inc., effective October 14, 2026. The company filed the current report on Form 8-K under Item 5.02(b) to disclose the departure. The 8-K did not include a transition plan, interim replacement, or other compensatory details.
Key takeaways
Chief Medical Officer departure: Dr. Nataliya Agafonova informed management on October 7, 2026 of her decision to step down as Chief Medical Officer, effective October 14, 2026.
Filing context: Longeveron disclosed the departure on Form 8-K, Item 5.02(b), signed by Chief Executive Officer Stephen Willard on October 14, 2026.
No replacement or transition terms: The 8-K did not disclose an interim or permanent successor, separation terms, or transition arrangements.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow LGVN in real time
Get material earnings, filing, IR, and earnings-call alerts by email.